Department of Health Economics, College of Health Management, Harbin Medical University, Harbin, China.
Department of Health Economics, College of Health Management, Harbin Medical University, Harbin, China
BMJ Open. 2021 Jul 1;11(7):e046742. doi: 10.1136/bmjopen-2020-046742.
This study analyses the cost-effectiveness of annual low-dose CT (LDCT) screening of high-risk cancer populations in Chinese urban areas.
We used a Markov model to evaluate LDCT screening from a sociological perspective.
The data from two large lung cancer screening programmes in China were used.
The sample consisted of 100 000 smokers who underwent annual LDCT screening until age 76.
The study comprises five screening strategies, with the initial screening ages in both the screening strategies and their corresponding non-screening strategies being 40, 45, 50, 55 and 60 years, respectively.
The incremental cost-effectiveness ratio (ICER) between screening and non-screening strategies at the same initial age was evaluated.
In the baseline scenario, compared with those who were not screened, the specific mortality from lung cancer decreased by 18.52%-23.13% among those who underwent screening. The ICER of LDCT screening ranges from US$13 056.82 to US$15 736.06 per quality-adjusted life year, which is greater than one but less than three times the gross domestic product per capita in China. An initial screening age of 55 years is the most cost-effective strategy.
Baseline analysis shows that annual LDCT screening of heavy smokers in Chinese urban areas is likely to be cost-effective. The sensitivity analysis reveals that sensitivity, specificity and the overdiagnosis rate influence the cost-effectiveness of LDCT screening. All scenarios tested demonstrate cost-effectiveness, except for the combination of worst values of sensitivity, specificity and overdiagnosis. Therefore, the cost-effectiveness of a screening strategy depends on the performance of LDCT screenings.
本研究分析了中国城市高危癌症人群年度低剂量 CT(LDCT)筛查的成本效益。
我们使用马尔可夫模型从社会学角度评估 LDCT 筛查。
使用了来自中国两项大型肺癌筛查计划的数据。
样本包括 100000 名吸烟者,他们接受了每年一次的 LDCT 筛查,直到 76 岁。
研究包括五种筛查策略,在筛查策略和相应的非筛查策略中,初始筛查年龄分别为 40、45、50、55 和 60 岁。
在相同初始年龄下,筛查策略与非筛查策略之间的增量成本效益比(ICER)进行了评估。
在基线情况下,与未筛查者相比,接受筛查者的肺癌特定死亡率降低了 18.52%-23.13%。LDCT 筛查的 ICER 范围为每质量调整生命年 13056.82-15736.06 美元,大于但小于中国人均国内生产总值的三倍。初始筛查年龄为 55 岁是最具成本效益的策略。
基线分析表明,对中国城市地区重度吸烟者进行年度 LDCT 筛查可能具有成本效益。敏感性分析表明,敏感性、特异性和过度诊断率影响 LDCT 筛查的成本效益。除了敏感性、特异性和过度诊断的最坏值组合外,所有测试的情景均显示出成本效益。因此,筛查策略的成本效益取决于 LDCT 筛查的性能。